Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates.
Glycopeptide-resistant Enterococcus faecium has emerged as an important nosocomial pathogen with limited therapeutic options. Here we report the successful treatment of glycopeptide-resistant E. faecium infection in two very low birth weight premature infants with the new oxazolidinone linezolid. Treatment with linezolid at a dosage of 10 mg/kg every 8 h intravenously for a duration of 16 days and 14 days, respectively, was well tolerated and led to complete clinical recovery and clearance of the organism from all body sites. The two cases support the clinical efficacy and safety of linezolid in very low birth weight premature neonates with glycopeptide-resistant E. faecium infections.
Hoehn
Rene
R
Department of Pediatrics, Johann Wolfgang Goethe University Hospital, Frankfurt/Main, Germany.
Groll
Andreas H
AH
Schaefer
Volker
V
Bauer
Karl
K
Schloesser
Rolf L
RL
D000081:Acetamides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D016984:Enterococcus faecium / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D005260:Female; D006020:Glycopeptides / Q000494:pharmacology*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D000069349:Linezolid; D008297:Male; D023303:Oxazolidinones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D047928:Premature Birth; D012449:Safety
D000081:Acetamides; D006020:Glycopeptides; D023303:Oxazolidinones; D000069349:Linezolid